- SKYRIZI is now the only four-dose-a-year biologic for psoriasis with options to administer via a single-dose pen or prefilled syringe NORTH CHICAGO, Ill., Aug. 9, 2021 /PRNewswire/ -- AbbVie (NYSE: ...
Skyrizi ® (risankizumab-rzaa) is now available as a single-dose 150mg prefilled pen or syringe for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic ...
Biologic treatment effectiveness in psoriasis January 2022 FDA drug approvals include treatments for asthma, psoriatic arthritis, insomnia, and atopic dermatitis. The US Food and Drug Administration ...
On Wednesday, AbbVie Inc. (NYSE:ABBV) reported third-quarter adjusted EPS of $3.00, up from $2.95 a year ago, beating the consensus of $2.92. Net revenues reached $14.46 billion, up 3.8%, beating the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback